CYP4A22

Across TCGA pan-cancer cohorts, CYP4A22 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CYP4A22’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where CYP4A22 RNA is repressed in tumor relative to normal tissue. In most cancer types CYP4A22 is over-expressed in tumor, although a few such as KIRP and LIHC show the opposite, repressed pattern.

KIRP, LIHC, and KICH are the cancer types where CYP4A22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP4A22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	IV	−4.952	<.001	11	view →
LIHC	Female	II,III,IV	−2.602	<.001	9	view →
KICH	All	II,III,IV	−2.880	<.001	8	view →
KIRC	Male	All	−1.351	<.001	8	view →
CHOL	All	All	−5.708	<.001	5	view →
LUSC	Male	II,III,IV	−0.132	<.001	4	view →
LUAD	Male	III,IV	−0.073	.009	3	view →
HNSC	Male	III,IV	−0.019	.019	3	view →
BRCA	All	All	+0.118	.044	2	view →
ESCA	All	All	−0.053	.012	1	view →
THCA	All	All	+0.015	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CYP4A22–KIRP

Open the KIRP breakdown →